207_Combined course Presentations

Umbrella trials matching patients to therapies based on molecular profiles

Primary outcome measure(s)

Program name

Lead organization

# Expected to accrue

Clinicaltrials.g ov identifier

Design

Histology Indication

Stage IB–IIIA lung adenocarcino ma Stage IB–IIIA adenocarcino ma of lung, with ALK fusion Stage IB–IIIA adenocarcino ma of lung, with activating EGFR mutation

Feasibility, genotyping for placement on adjuvant trials

US National Cancer Institute

Enrichment, research

ALCHEMIST

Screening 8,000

NCT02194738

ECOG-ACRIN R

Adjuvant

378

OS

NCT02201992

ALLIANCE R

Adjuvant

450

OS

NCT02193282

BATTLE-2 MD Anderson A–R

NSCLC

Metastatic 450

8-Week DCR NCT01248247

Variable (maximum 2,329)

EudraCT# 2012-005111- 12 (37)

Cancer Research UK

FOCUS 4

R

Colorectal

Metastatic

PFS